Skip to content

How to Better Identify HER2-Low Breast Cancer

Release Date: 12 Jun 2023 MedPage Today
College of American Pathologists Logo

David Rimm, MD, PhD, FCAP, explains how pathologists can better distinguish IHC 1+/2+ from 0. "I'll be presenting a poster discussion on low HER2," said Dr. Rimm. "The title is 'Are We Splitting HERs?' -- a pun on hairs. But splitting is because the new drugs, the ADC [antibody-drug conjugate] trastuzumab deruxtecan [Enhertu], is indicated for patients that have HER2 1+ or 2+ IHC, but not HER2 0. And the question is, can we split those?"

For the full article click here: How to Better Identify HER2-Low Breast Cancer

adding all to cart
False 0
File added to media cart.